Next Article in Journal
Antibiotic Activity Potentiation and Physicochemical Characterization of the Fixed Orbignya speciosa Almond Oil against MDR Staphylococcus aureus and Other Bacteria
Next Article in Special Issue
A Review of the Clinical Pharmacokinetics of Polymyxin B
Previous Article in Journal
Genetic Profiling and Comparison of Human and Animal Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Serbia
Previous Article in Special Issue
Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia

Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Room 164 (M/C 886), Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Antibiotics 2019, 8(1), 27; https://doi.org/10.3390/antibiotics8010027
Submission received: 25 February 2019 / Revised: 8 March 2019 / Accepted: 12 March 2019 / Published: 16 March 2019
(This article belongs to the Special Issue Proceedings from the 3rd International Conference on Polymyxins)

Abstract

Despite advancements in therapy, pneumonia remains the leading cause of death due to infectious diseases. Novel treatment strategies are desperately needed to optimize the antimicrobial therapy of patients suffering from this disease. One such strategy that has recently garnered significant attention is the use of inhaled antibiotics to rapidly achieve therapeutic concentrations directly at the site of infection. In particular, there is significant interest in the role of inhaled polymyxins for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, due to their retained activity against multi-drug resistant Gram-negative pathogens, including Acinetobacter baumannii and Pseudomonas aeruginosa. This review will provide a comprehensive overview of the pharmacokinetic/pharmacodynamic profile, clinical outcomes, safety, and potential role of inhaled polymyxins in clinical practice.
Keywords: colistin; polymyxin; HAP; VAP; pneumonia; inhaled antibiotics colistin; polymyxin; HAP; VAP; pneumonia; inhaled antibiotics

Share and Cite

MDPI and ACS Style

Biagi, M.; Butler, D.; Tan, X.; Qasmieh, S.; Wenzler, E. A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia. Antibiotics 2019, 8, 27. https://doi.org/10.3390/antibiotics8010027

AMA Style

Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E. A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia. Antibiotics. 2019; 8(1):27. https://doi.org/10.3390/antibiotics8010027

Chicago/Turabian Style

Biagi, Mark, David Butler, Xing Tan, Samah Qasmieh, and Eric Wenzler. 2019. "A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia" Antibiotics 8, no. 1: 27. https://doi.org/10.3390/antibiotics8010027

APA Style

Biagi, M., Butler, D., Tan, X., Qasmieh, S., & Wenzler, E. (2019). A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia. Antibiotics, 8(1), 27. https://doi.org/10.3390/antibiotics8010027

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop